INTRODUCTION
Ovarian cancer (OvCa) has a high mortality rate among all gynecological tumors. 1, 2 Despite adequate patient responsiveness to surgery and chemotherapy, the long-term prognosis remains poor. 3 Most (75%-80%) patients are diagnosed when the disease is advanced (stages III and IV); the 5-year survival rate for patients with stage III OvCa is ,40% and ,20% for stage IV patients. Furthermore, 30%-40% of patients with stage I and II OvaCa experience disease relapse, even after initial successful chemotherapy. 4 Novel therapeutic strategies are therefore needed to prevent both the recurrence and progression of this disease. Immunotherapies, including therapeutic dendritic cell (DC) vaccines, which are designed to induce tumor-specific immunity, represent promising strategies.
Therapeutic anti-cancer DCs are ex vivo cultured from peripheral blood monocytes in combination with growth factors and cytokines, including granulocyte-macrophage colonystimulating factor (GM-CSF) gm-CSF and IL-4. To induce tumor-specific immunity, antigens are pulsed in the form of tumor lysates, peptides or RNA. In addition, keyhole limpet hemocyanin (KLH) has been added as an indicator of DC vaccine-induced immune responses. Although KLH induces immune responses, it is not clear whether KLH influences the functionality of DC vaccines.
DC-based vaccinations in human solid cancers activate the immune system to detect and destroy tumor cells. The safety and feasibility of anti-cancer DC vaccines have been confirmed in several clinical trials. [5] [6] [7] [8] [9] The clinical response of DC vaccines targeting OvCa has recently been published. [10] [11] [12] [13] These reports investigated the frequency of regulatory T cells (Tregs) as an effective means to reveal the efficacy of the vaccine. The elimination of Tregs could be an important prerequisite for a successful anti-cancer vaccine. However, no significant correlation between clinical responses and alterations in Treg proportions has been observed after DC treatment in OvCa patients. [10] [11] [12] [13] DC stimulation of anti-tumor T cells might be enhanced through cytokines that promote T-cell expansion in vivo. Recombinant IL-2 is a potent stimulator of lymphocyte proliferation through the modulation of CTL activity.
14 Although limited, previous studies have shown the induction of Tregs through IL-2, 15, 16 and the systemic administration of low doses of IL-2 exhibits a broad range of immunological effects, including the induction of specific T helper and natural killer (NK) cells. 17 The present study is a phase I/II clinical trial, characterizing the toxicity and immune responses of the DC vaccine combined with IL-2 to determine the clinical relevance of this treatment in the OvCa patients. The DC vaccination in combination with IL-2 was well tolerated and induced longterm clinical responses and overall survival. The relevance of DC vaccination-induced immune modulation to clinical responses and overall survival will be discussed.
MATERIALS AND METHODS

Culture media and reagents
The DCs were cultured in complete medium containing X-VIVO 20 (BioWhittaker, Walkersville, MD, USA) supplemented with 1% human albumin (Green Cross, Seoul, South Korea), 2 mM glutamine (Gibco, Grand Island, NY, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). Recombinant human GM-CSF (LG Life Sciences, Seoul, South Korea), IL-4 and TNF-a (R&D Systems, Minneapolis, MN, USA) were used to generate DCs. The amounts of IFN-c, IL-10, IL-12, TGF-b and vascular endothelial growth factor (VEGF) in DCs or patient plasma samples were measured using commercially available ELISA kits (eBioscience, San Jose, CA, USA). KLH was obtained from Calbiochem (La Jolla, CA, USA). IL-2 (Proleukin) was obtained from Novartis (Basel, Switzerland). K562, a target cell used in the NK activity assay, is a human chronic myelogenous leukemia cell line purchased from the American Type Culture Collection (# CCL-243; ATCC, Manassas, VA, USA).
Patient criteria
The clinical trial protocol for this study was approved through ), renal (serum creatinine within one and a quarter of normal range) and hepatic (serum SGOT/SGPT within three times the normal range) activity were enrolled. The median age of the patients was 44 years (range: 37-60 years). Nine patients had stage III (one IIIA, one IIIB and seven IIIC) and one patient had stage IV ovarian cancer with metastasis ( Table 1) .
Generation of therapeutic DCs
The successful collection of peripheral blood mononuclear cells (PBMCs) and generation of therapeutic DCs was achieved in the 10 patients enrolled in the vaccine trial. Therapeutic-DCs were manufactured for clinical use according to the Good Manufacturing Practice-compliant facility (FCB-Pharmicell Co. Ltd, Sungnam, South Korea). PBMCs were harvested from the patients through leukapheresis using Cobe Spectra (Gambro BCT Inc., Lakewood, CA, USA) after mobilization with recombinant human G-CSF (Leucostim; Dong-A Pharmaceutical, Seoul, South Korea) at 300 mg/day, administered subcutaneously for 5 days. The PBMCs were collected at 3-4 weeks (228 to 221 days) before the first planned vaccination (day 0). To generate monocyte-derived DCs, the PBMCs were adhered onto a T75 culture flask (Corning, Tewksbury, MA, USA) for 2 h at 37 uC. The adherent cells were further cultured in complete medium supplemented with GM-CSF (100 ng/ml) and IL-4 (25 ng/ml) for 7 days. On day 7, TNFa (10 ng/ml) was added to the culture, and the cells were incubated for 2 additional days. On day 8, autologous tumor lysate (30 mg/ml) and 1 mg/ml of KLH (Calbiochem) were added to the cultures, and the cells were further incubated overnight. To obtain the autologous tumor lysate, resected tumors were minced and digested in sterile tissue digestion medium containing 0.5 mg/ml of type IV collagenase (Sigma C-2139; Sigma, St Louis, MO, USA) and 75 U/ml deoxyribonuclease I (Sigma D-5025) at 37 uC for 30 min. The single cell suspension was subsequently washed, and the resulting cell pellet was harvested. The cell pellet was subjected to five freezing/thawing cycles (in the liquid nitrogen and 37 uC water bath), and the resulting single cell suspension was stored at 280 uC until further use. The protein concentration of the tumor lysate was spectrophotometrically determined at 595 nm using Coomassie Plus-The Better Bradford Assay Kit (Pierce, Rockford, IL, USA). On day 9, the antigen-pulsed therapeutic DCs were harvested, washed and resuspended at a final concentration of 1310 7 cells/ml in saline solution. The criteria for the release of clinical grade DCs was greater than 80% viability and the absence of microbial contamination (bacteria, fungus and mycoplasma) with intact phenotype and function ( Figure 2 ). The in-house release criteria for the therapeutic DC phenotype was greater than 70% HLA-DR 1 and CD11c 1 , with greater than 50% B7 expression.
Vaccination protocol
Three to seven months after the initial surgery and chemotherapy, 10 patients were treated with lysate-loaded DCs (4.13310 7 60.27310 7 cells/injection), followed by 14 consecutive IL-2 (200 mIU) injections in a single vaccination protocol. Two vaccinations were subcutaneously administered in an area adjacent to the axillary lymph node at 4-week intervals. The most common site for the DC infusion is the draining lymph node at the disease site. OvCa patients in this protocol experienced initial debulking surgery, resulting in the lack of inguinal draining lymph nodes. Thus, as a second choice, DCs were injected adjacent to the axillary lymph node. The DC vaccine-induced clinical outcome was determined at 14 weeks after the first DC injection, and long-term follow-up continued until February 2012 ( Table 2 ). The immune responses were evaluated at 0 (pre) and 8 weeks (post) after the first DC injection ( Figure 1 ). The clinical outcome was measured as a complete response (CR), indicating the elimination of tumor, a partial response (PR), indicating over 50% reduction in the existing tumor, or stable disease (SD), indicating 25%-50% reduction in the existing tumor or less than 25% induction of tumor burden after DC vaccination. Progressed disease (PD) indicated a greater than 25% induction of tumor burden. The progression-free survival period was observed, and the disease status was expressed as no evidence of disease (NED) or alive with disease (AWD) in the long-term follow-up.
Immune monitoring NK activity. To generate effector cells (E), lymphocytes were prepared from peripheral blood through density-gradient separation using lymphocyte separation medium (Cellgro; Mediatech, Manassas, VA. USA). Log-phase K562 cells, a human chronic myelogenous leukemia cell line sensitive to NK cell killing, were labeled with Na 2 51 CrO 4 and used as target cells (T). The labeled K562 cells (1310 4 cells/well) and selected concentration of effecter cells (E/T525 : 1 or 50 : 1) were seeded onto U-bottomed 96-well microtiter plates. After 4 h of incubation at 37 uC in a humidified 5% CO 2 incubator, the supernatant was removed, and the levels of radioactivity were assessed using a Wallac 1470 Wizard gamma counter (Perkin Elmer. Turku, Finland). The spontaneous (SR) and total release (TR) were measured in the supernatants of target cells incubated with either culture medium or 1 N HCl. The NK cell activity was calculated as
Phenotypic analysis. Peripheral blood was obtained from the patients before (pre: 0 week) and after vaccination (post: 18 weeks). The lymphocytes were purified through densitygradient separation using lymphocyte separation medium (Cellgro; Mediatech). Subsequently, the lymphocytes were incubated with fluorescence (either FITC or PE)-tagged antibodies Therapeutic DC vaccination for ovarian cancer S Baek et al for 40 min at 4 uC, and fluorescence was detected within 2 h after antibody staining using FACSVantage (Becton-Dickson, Mountain View, CA, USA). The following antibodies were utilized: anti-CD16/CD56 for the NK cell subset and anti-CD4/ CD25 for the regulatory T-cell subset (BD Pharmingen, San Diego, CA, USA). Mouse IgG1-FITC and mouse IgG2a-RPE (DAKO, Glostrup, Denmark) were used as negative controls.
Lymphocyte proliferation assay. Heparinized blood samples were collected before and 8 weeks after the first DC injection. The separated blood lymphocytes were seeded in triplicate onto 96-well plates (2310 5 cells/well) containing KLH (50 mg/ml) and incubated at 37 uC in humidified and 5% CO 2 -conditioned air for 4 days. The cultures were loaded with 1 mCi 3 H-thymidine/well (Perkin-Elmer Inc., Boston, MA, USA) for 18 h. The cells were harvested on glass microfiber filters using a PhD cell harvester (Cambridge Technology Inc., Cambridge, MA, USA). The proliferative response was determined through 3 H-thymidine incorporation using a liquid scintillation counter (Beckman LS 6500; Beckman Instruments Inc., Fullerton, CA, USA).
Analysis of IFN-c-producing cells using an enzyme-linked immunospot (ELISPOT) assay. The ELISPOT assay was adopted to detect the secretion of IFN-c protein from individual cells in vitro upon exposure to antigen. The ELISPOT IFN-c kit was purchased from AID (Strassberg, Germany), and the assays were performed according to the manufacturer's instructions. Briefly, using a magnetic bead cell separation system (MACS TM Miltenyi Biotec, Bergisch Gladbach, Germany), the CD3 1 T cells were purified from the peripheral lymphocytes (2310 5 cells) and stimulated in vitro with KLH on a 96-well precoated plate. The plate was incubated for 20 h at 37 uC with 5% CO 2 . After washing, a detection antibody was added into each well, and the cells were incubated for 2 h at room temperature. The plate was subsequently incubated with alkaline phosphatase conjugate and developed using a BCIP/NBT substrate solution. The visible spots were enumerated using an automated AID ELISPOT reader (AID) and the default program.
Measurement of cytokine levels. Alterations in blood-circulating concentrations of IL-12, TGF-b, IFN-c, IL-10 and VEGF during immunotherapy were measured using ELISA. Plasma was obtained from peripheral blood samples collected before and after treatment and stored at 270 uC until the ELISA was performed using commercial kits: OptEIA (eBioscience) for IL-12, TGF-b, IFN-c, IL-10 and Quantikine (R&D Systems Inc.) for VEGF.
Statistical analysis
The values before and after vaccination were used for the analysis of the immune response and compared using Student's t-test. Values of P,0.05 were considered statistically significant.
RESULTS
Characteristics of the cultured DCs
Therapeutic DCs were derived from adherent monocytes cultures obtained from PBMCs using GM-CSF and IL-4. TNF-a was added as a maturation factor, and the cells were incubated for an additional 2 days. The cells differentiated into DCs, as observed under the microscope (Figure 2a) . The cultured cells exhibited a DC phenotype, and the mean values for the 10 
Abbreviations: AWD, alive with disease; F/U loss, follow-up loss; NA, not available; NED, no evidence of disease; PFS, progression-free survival; OS, overall survival. ", increased compared with baseline; "", highly increased compared with baseline; #, decreased compared with baseline. a Indicates outcome at 14 weeks after first DC injection. b PFS and OS indicates months after diagnosis. 
DC vaccine-induced clinical responses
As a consolidation therapy, the DC vaccine, in combination with IL-2, was subcutaneously injected into an area adjacent to the axillary lymph node. The vaccine was well tolerated in all patients. The most common side effects were flu-like symptoms ( Table 1) .The clinical and immunological responses after DC vaccination are summarized in Table 2 . The initial CR inclusion status was maintained in three patients (patients H, K and Y) after DC vaccination for 83, 80.9 and 38.2 months, respectively, without disease relapse. However, for the remaining CR patients (patients J, S, T and X), the disease-free status was not maintained in the long-term follow-up, even after DC vaccination. Although patient T expired upon disease relapse, the remaining patients survived. The best-case scenario was observed with patient V, whose inclusion status was SD. After DC vaccination, the remaining disease completely disappeared, and this disease-free status was maintained for 50.8 months until tumor recurrence. The recurring disease responded to chemotherapy, resulting in the long-term disease-free survival of patient V. The two patients whose inclusion status was PR did not respond to DC vaccination, and disease recurrence was observed. The outcome of short-term DC vaccination (14 weeks after the first DC injection) was 50% CR (5 out of 10 patients). In February 2012, the overall survival associated with DC vaccination was determined in six followup patients as 38.2-83.0 months (64.9567.62 months), with or without disease.
Treatment-associated modulation of NK activity and cytotoxic NK cell proportion
To determine the influence of DC vaccination on NK cell activity, peripheral blood lymphocytes were collected before (w0) and after vaccination (w8). The NK cell activity significantly increased in five patients (patients H, J, P, T and Y) after the vaccination (Figure 3a ). An increase in the cytotoxic NK cell proportion (CD16 1   CD56 dim ) was observed in four (H, J, T and Y) of these five patients (Figure 3b ). Among these, two patients (patients H and Y) maintained NED status for 83 and 38.2 months, respectively. However, one patient (patient J) experienced disease recurrence at 21.8 months, and this patient was (Table 2) .
DC vaccine-induced modulation of systemic immunity
Lymphocyte proliferation and alteration of the CD4 1 CD25
1 T-cell proportion. The DC vaccine-associated lymphocyte activation was measured. Peripheral blood lymphocytes were stimulated in vitro with KLH, a surrogate marker for DC vaccination. KLH was pulsed into the DC with tumor lysate. Thus, it would be replaced the tumor lysate as an in vitro stimulant suggesting DC vaccine effects. A high dose of KLH alone is sufficient to induce immunity. In the present study, therapeutic DCs were pulsed with only 1 mg of KLH instead of 10-50 mg, which has been primarily used in previous DC vaccine trials. Thus, in the present study, KLH-induced immunogenicity might not override DC vaccine-induced immunity. DC vaccine-associated KLH-specific lymphocyte proliferation was observed in six (patients H, P, T, U, X and Y) of the 10 patients, and three patients (patients P, U and X) showed statistical significance ( Figure 4 ). In five of the six patients, a concomitant reduction in the proportion of CD4 
DISCUSSION
In the present phase I/II study, the clinical safety and immune modulation of consolidation therapy with DC-based cancer vaccines were investigated in 10 OvCa patients. The vaccine comprised autologous monocyte-derived DCs and IL-2. The therapeutic DCs secreted significant amounts of IFN-c (Figure 2c ). Because IFN-c is of central importance for the induction of robust cell-mediated immunity, 18,19 the therapeutic DCs used in the current study were expected to positively affect clinical and immune responses. The clinical response observed in the present study was better than that observed in a previous study of renal cell carcinoma or breast cancer patients. 7 The differences between these two studies reflect the characteristic secretion of IFN-c from therapeutic DCs. The vaccine was well tolerated and induced immune alterations ( Table 2 ). The most common side effects were flulike symptoms, which might result from the injection of IL-2. 21, 22 Five of the 10 patients who experienced CR after DC therapy maintained long-term survival (approximately 4 years after the vaccination), with (AWD in one patient) or without (NED in four patients) disease. However, four patients with objective SD or PD response after DC therapy experienced disease recurrence (follow-up loss or expiration), regardless of the inclusion status of initial therapy. The long-term follow-up results suggested a correlation between the DC vaccine response and overall survival.
Since 1994, many clinical studies of tumor antigen-loaded DC vaccines have been conducted 18 to analyze clinically relevant immune alteration parameters. Among the various cellular immune-monitoring methods, the ELISPOT assay is typically used to determine the frequency of effector cytokine (i.e., IFN-c)-secreting (CD8 1 ) T cells, and this assay has generated the most valuable results for evaluating the correlation between DC vaccine-induced immunological modulation and clinical response. 19 The value of the ELISPOT assay for measuring IFN-c-secreting T cells was also apparent in a previous study. 7 However, evidence for the importance of the tumor microenvironment and immune homeostasis in tumor development determined after measuring a single immunological parameter, such as cytotoxic T-cell activity, might not be sufficient to estimate the DC vaccine-induced anti-tumor response. We therefore measured immune-stimulatory and 
